Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @alliancerm
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @alliancerm
-
Prikvačeni tweet
Couldn't make it to the 2020 Cell & Gene Therapy State of the Industry Briefing? Video recordings are now available on ARM's YouTube page: https://www.youtube.com/user/AllianceRegenMed/videos …
#JPMWeek#JPM20#JPM2020#celltherapy#genetherapy#BioWeekSF#SOTI20pic.twitter.com/QDMwxwfcPr
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
Together with
@ParkwalkAdvisor and UKIS2, we have invested £2.5m seed funding to launch Ikarovec to further develop novel gene therapies for#diabeticmacularedema#dme. Learn more here: http://bit.ly/2tzxFti#translationalreseach#patientbenefitpic.twitter.com/Hrd2TTU7nO
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
From
@thehill Unlawful stem cell products continue to harm people as FDA deadline looms https://thehill.com/opinion/healthcare/480751-unlawful-stem-cell-products-continue-to-harm-people-as-fda-deadline-looms …#stemcells#stemcellHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
NEWS: We've dosed the 1st patient in a Phase 1 study using AAV
#genetherapy for the treatment of congestive heart failure. Thanks to Dr. Tim Henry and the@ChristHospital team! Read more at http://bit.ly/2SkTVzz .#HeartMonth
#cardiology#cardiovascularpic.twitter.com/jFBVeYMGsx
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO902 Gene Therapy in Patients with Overactive Bladder: Urovant Sciences Nasdaq UROV announced today the publication of the safety and efficacy results of URO902…http://bioportfol.io/RPMHrS
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
Passage ended 2019 with $158.9 million in the bank and now expects its phase 1/2 gangliosidosis trial to kick off in the second half of 2020, with trials for the dementia and Krabbe candidates to follow in the first half of 2021https://www.fiercebiotech.com/biotech/after-bagging-200m-2019-passage-bio-guns-for-125m-ipo …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A robust clinical pipeline, strong global financings, and the potential for immense benefit to patients: ARM CEO
@jlynchlambert shares her thoughts on the state of the regenerative medicine sector in 2019 and the outlook for 2020 – https://insights.bio/cell-and-gene-therapy-insights/journal/articles/state-of-the-industry-the-financial-clinical-and-scientific-landscape-for-cell-and-gene-therapies/ …pic.twitter.com/4mxD5qljUS
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
[PRESS RELEASE] Upon completion of the transaction, MaSTherCell and Catalent will position the new entity as a leading cell therapy platform in the industry! MaSTherCell’s Press Release: https://bit.ly/2UoMfPd / More info on Catalent's website: https://bit.ly/3b5Zg6j pic.twitter.com/WBVL9pXgCp
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Managing Uncertainty In Drug Value: Outcomes-Based Contracting Supports Value-Based Pricing – https://buff.ly/2O8ZIHa
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
$CNAT Conatus Pharmaceuticals and Histogen Enter into Definitive Merger AgreementHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
Cognate BioServices closes Series B and completes acquisition of Cobra Biologics https://buff.ly/38I5WWn
#funding#fundraising#investment#venturecapital#investors#biotech#pharma#biopharma#healthcare#businesspic.twitter.com/gUGdDLNwia
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
$CABA’s lead candidate, DSG3-CAART, has been granted Orphan Drug Designation by the
#FDA for the treatment of pemphigus vulgaris (PV) https://bit.ly/3aPCW0x#CAART#autoimmune#OrphanDrugpic.twitter.com/3wvtSxvs7t
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Penn researchers identify cancer cell defect driving resistance to
#CARTcell therapy –https://www.eurekalert.org/pub_releases/2020-01/uops-pri012820.php …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hitachi Chemical Advanced Therapeutics Solutions Announces Opening of Its New Facility Designed to Manufacture Commercial Cell and Gene Therapies:https://www.businesswire.com/news/home/20200130005221/en/Hitachi-Chemical-Advanced-Therapeutics-Solutions-Announces-Opening …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
Rare disease biotech Passage Bio nabs Deerfield veteran as CEO http://dlvr.it/RNzxtb pic.twitter.com/qUx1bHAMR9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
PRESS RELEASE: Orchard Therapeutics Announces FDA Granted Orphan Drug Designation for OTL-102 for the Treatment of X-linked Chronic Granulomatous Disease (X-CGD). Learn more: http://ow.ly/Hd1E50y89OQ pic.twitter.com/kL47ECqRw9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
Today the Marketing Authorization Application for our second
#CARTcell therapy was validated for review by the European Medicines AgencyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
With new rules, FDA aims to spark competition, lower prices for expensive gene therapies https://www.statnews.com/2020/01/28/new-fda-rules-gene-therapies/ … via
@statnewsHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
Novartis said approximately 200 patients have been treated with Zolgensma, a lifesaving gene therapy for infants and the world’s most expensive medicine.https://buff.ly/2tZOcqC
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ARM proslijedio/la je Tweet
Very sad news for the evidence-based treatment of patients and for companies focussed on ethical research. U.S. judge rejects FDA bid to shut down stem cell clinics, dealing blow to regulatorshttps://www.latimes.com/business/story/2020-01-28/judge-fda-stem-cell-clinics …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.